Recursion is building an industrialized engine for medicine. It operates among biotech stocks, selling access to its proprietary platform and pursuing joint development with major partners like Roche ...

Recursion Pharmaceuticals is trying to solve a serious problem. Even with technological improvements, the time and costs required to develop brand-new drugs have increased in recent decades. It can ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

The companies at the frontier of artificial intelligence should be ready to slow down, one of the fastest-moving among them says. Anthropic, the maker of the Claude chatbot, has claimed AI systems may ...

The artificial intelligence giant said a “brake pedal” was needed to protect humanity from self-improving models. The proposal could have big consequences. By Andrew Ross Sorkin Bernhard Warner Sarah ...

Asana has acquired the workflow automation company StackAI for $75 million, part of a larger effort to position itself as an AI-native workplace platform. StackAI’s founders, Tony Rosinol and Bernard ...

As artificial intelligence (AI) speeds up and simplifies technical tasks, the ability to think creatively and communicate visually will be the competitive edge that sets the next generation of data ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Anthropic said its powerful new AI model, Mythos, could be dangerous in the wrong hands. WSJ’s Nicole Nguyen explains why and shares some cybersecurity tips for the average tech user. Photo: Sean ...

Anthropic says AI could soon improve without human intervention Development pause will allow society to deal with AI's implications, startup says Previous attempts to halt AI progress have not been ...

Adam Hayes, Ph.D., CFA, is a financial writer with 15+ years Wall Street experience as a derivatives trader. Besides his extensive derivative trading expertise, Adam is an expert in economics and ...